CellaVision (CEVI) Q2 2024 earnings summary

Executive summary

• Net sales grew 11% year-over-year to SEK 188 million in Q2 2024, with 10% organic growth and minimal FX impact, driven by strong APAC and EMEA performance and a temporary downturn in the Americas due to operational issues.

• EBITDA reached SEK 60 million, representing a 32% margin, exceeding the 30% target and showing improvement over the previous year.

• Strategic alliance with Sysmex advanced, with increased collaboration and integration at multiple organizational levels.

• Internal clinical studies for bone marrow applications completed; external validation planned for H2 2024, targeting commercialization in 2025.

Financial highlights

• Q2 2024 net sales: SEK 188 million (170 million), gross profit: SEK 125 million (119 million), gross margin: 66% (70%).

• EBITDA: SEK 60 million (56 million), profit before tax: SEK 48 million (44 million), EPS: SEK 1.62 (1.46).

• Operating expenses: SEK 75 million (73 million) in Q2 2024, reflecting cost control and restructuring benefits.

• Cash flow from operating activities: SEK 40 million (28 million); total cash flow: -SEK 44 million after investments and dividends.

• Cash and cash equivalents at quarter-end: SEK 122 million (35 million); equity ratio: 77% (73%).

Outlook and guidance

• Price increases implemented in Q2 are expected to positively impact gross margin in the second half of 2024.

• Commercial launch of bone marrow application anticipated in 2025, pending regulatory approval.

• Ongoing collaboration with Sysmex to drive joint commercialization and expand market presence.

• Temporary operational slowdown in Americas expected to recover in Q3.